Literature DB >> 17553654

Age influences TSH serum levels after withdrawal of l-thyroxine or rhTSH stimulation in patients affected by differentiated thyroid cancer.

Teresa Montesano1, Cosimo Durante, Marco Attard, Umberto Crocetti, Domenico Meringolo, Rocco Bruno, Salvatore Tumino, Domenico Rubello, Adil Al-Nahhas, Marzia Colandrea, Marianna Maranghi, Laura Travascio, Giuseppe Ronga, Massimo Torlontano.   

Abstract

Recombinant human TSH (rhTSH) has been recently suggested for radioiodine ablation in patients with differentiated thyroid cancer (DTC). To date, studies are still not available about the effectiveness of rhTSH stimulation depending on the age, since serum TSH clearance may be different in younger and in older patients. The aim of this study was to investigate the influence of age to serum TSH levels after rhTSH stimulation and thyroid hormone withdrawal (THW). We retrospectively evaluated two groups of consecutive DTC patients: group 1 (311 patients, age 49.0+/-13.6 years, ranging 15-86) underwent rhTSH stimulation 6-12 months after thyroid ablation (rhTSH-group); group 2 (84 patients, age 46.9+/-13.5 years, ranging 20-77) was followed by THW (THW-group). The influence of age, gender, body mass index and body surface area to serum TSH levels were evaluated in both groups. RhTSH-group: on day 5 (d5), TSH levels were 32.7+/-21.4 microU/ml (range 0.8-136.6). By univariate analysis, d5-TSH was positively related to age (r=0.27, p=0.0001) and no correlations were found with the other parameters. At multivariate analysis, both age and gender (female) were independently associated with d5-TSH levels. THW-group: after thyroid hormone withdrawal, TSH levels were 71.1+/-36.4 microU/ml (range 8.5-200). At univariate analysis, only age was significantly and negatively related to serum TSH levels (r=-0.31, p=0.004). Our data indicate that age and gender seem to positively influence serum TSH levels after rhTSH stimulation. An opposite effect of age on serum TSH levels has been observed after THW. Therapeutic implications ((131)I-treatment) of these findings have to be better investigated in prospective studies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17553654     DOI: 10.1016/j.biopha.2007.04.001

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  8 in total

1.  Age modifies the response to recombinant human thyrotropin.

Authors:  Rebecca Over; Hala Nsouli-Maktabi; Kenneth D Burman; Jacqueline Jonklaas
Journal:  Thyroid       Date:  2010-10-18       Impact factor: 6.568

Review 2.  Recombinant human thyrotropin (rhTSH) aided radioiodine treatment for residual or metastatic differentiated thyroid cancer.

Authors:  Chao Ma; Jiawei Xie; Wanxia Liu; Guoming Wang; Shuyao Zuo; Xufu Wang; Fengyu Wu
Journal:  Cochrane Database Syst Rev       Date:  2010-11-10

Review 3.  Potential use of recombinant human thyrotropin in the treatment of distant metastases in patients with differentiated thyroid cancer.

Authors:  Joanna Klubo-Gwiezdzinska; Kenneth D Burman; Douglas Van Nostrand; Mihriye Mete; Jacqueline Jonklaas; Leonard Wartofsky
Journal:  Endocr Pract       Date:  2013 Jan-Feb       Impact factor: 3.443

4.  Analysis of Clinical Factors for the Determination of Optimal Serum Level of Thyrotropin After Recombinant Human Thyroid-Stimulating Hormone Administration.

Authors:  Seung Hyun Son; Sang-Woo Lee; Ji-Hoon Jung; Choon-Young Kim; Do-Hoon Kim; Shin Young Jeong; Byeong-Cheol Ahn; Jaetae Lee
Journal:  Nucl Med Mol Imaging       Date:  2015-09-01

5.  Recombinant human thyroid stimulating hormone in 2008: focus on thyroid cancer management.

Authors:  Ann Gramza; Kathryn G Schuff
Journal:  Onco Targets Ther       Date:  2009-01-01       Impact factor: 4.147

Review 6.  rhTSH-aided low-activity versus high-activity regimens of radioiodine in residual ablation for differentiated thyroid cancer: a meta-analysis.

Authors:  Chao Ma; Limin Tang; Hongliang Fu; Jianing Li; Hui Wang
Journal:  Nucl Med Commun       Date:  2013-12       Impact factor: 1.690

7.  Is Very High Thyroid Stimulating Hormone Level Required in Differentiated Thyroid Cancer for Ablation Success?

Authors:  Zekiye Hasbek; Bülent Turgut
Journal:  Mol Imaging Radionucl Ther       Date:  2016-06-05

8.  Indirect Basal Metabolism Estimation in Tailoring Recombinant Human TSH Administration in Patients Affected by Differentiated Thyroid Cancer: A Hypothesis-Generating Study.

Authors:  Agnese Barnabei; Lidia Strigari; Agnese Persichetti; Roberto Baldelli; Laura Rizza; Claudia Annoscia; Rosa Lauretta; Giovanni Cigliana; Maddalena Barba; Aurora De Leo; Marialuisa Appetecchia; Francesco Torino
Journal:  Front Endocrinol (Lausanne)       Date:  2018-02-15       Impact factor: 5.555

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.